Biosciences

SomaLogic, spun out of the Gold Lab at ��ý�Ļ��Ʒ, revolutionized protein discovery methods to provide insights into disease discovery and treatment

Daniel Corbin Leonard — Wed, 30 Oct 2024 20:38:57 +0000

SomaLogic, spun out of the Gold Lab at ��ý�Ļ��Ʒ, revolutionized protein discovery methods to provide insights into disease discovery and treatment Daniel Corbin … Wed, 10/30/2024 - 14:38

Heather Hansen

Founded by ��ý�Ļ��Ʒ Professor Larry Gold in 2000, SomaLogic revolutionized protein measurement by developing a faster, cost-effective process to monitor the vast number of proteins in the human body. Gold’s discoveries and work at ��ý�Ļ��Ʒ ultimately led to the creation of three spinout companies and a significant impact on global healthcare research and diagnostics.

Like most groundbreaking biotechnology companies, SomaLogic formed around a problem to solve—how to precisely measure the huge number of proteins in the human body. In 2000, when Larry Gold founded the company, measuring proteins was a time-consuming, costly and flawed process reliant on antibodies which are often not specific or sensitive enough detection tools.

Larry Gold, PhD

Gold, who began teaching in the University of Colorado Boulder’s Molecular, Cellular & Developmental Biology (MCDB) department in 1970 (and served as its chair from 1988 to 1992), set out to do what no one else in the world was doing at the time—measure proteins more simply, cheaply and quickly. “My whole career at CU in MCDB, for 50 plus years, I have cared about measuring proteins,” said Gold.

Measuring proteins is so important because they’re the building blocks of life. The human body has at least 20,000 different proteins—and many more variants—working together in a complicated choreography. For example, collagen is a protein that structures skin, bones and teeth, while hemoglobin carries oxygen in blood. Proteins are also key to a well-functioning immune system, catalyze reactions in the body, and function as critical messengers within and between cells.

The ability to identify and count proteins is essential to biomedical research. Quantifying protein concentrations can help measure the presence and progression of diseases like cancer, heart disease and Alzheimer’s. Proteins are also often the targets of therapeutics—like aspirin for a headache—because of all the biochemical processes they carry out and their ability to intervene in pathologies with high specificity.

At the start, Gold’s lab could measure roughly 70 proteins by working long hours and sticking with the process despite occasional setbacks. For decades, said Gold, “From morning to night, seven days a week, oftentimes all night, I pipetted the same experiment thousands of times,” he said. “I don’t get bored doing the same thing over and over as long as we’re learning stuff—and we were.”

Gold said advancing their knowledge of proteins little by little while enjoying the camaraderie of life in the lab made long hours and ‘failed’ experiments tolerable, even enjoyable. “You can’t get upset when an experiment doesn't work, it’s a continuing, iterative process,” he said. “And I was doing it with good people–and that’s fun.”

Their process was cutting-edge at the time, but Gold knew that to crack the code on proteins, they’d need to be able to measure more and faster. That mission was the driving force in founding SomaLogic. “The tech for what we wanted to do didn’t exist, so we had to invent it on the spot,” Gold told an entrepreneur forum in 2015. “The basic idea was right about what we wanted to do, but the technology was harder than we thought,” he said.

Inventing those tools ultimately would take a decade and $200 million.

Imagining a bold future

In a way, proteins are like locks that Gold and his team were trying to find keys to. That matchmaking effort began decades ago, leading to an underlying innovation that fueled three spinouts and countless ongoing applications.

In the late 1980s, Gold and his team at ��ý�Ļ��Ʒ, including PhD student Craig Tuerk, made a discovery that led to that original innovation. They were developing a technique to identify molecules that would selectively bind to other compounds (based on a piece of ribonucleic acid, or RNA, which Tuerk was studying).

Gold recalled the day when—two years into an experiment he’d asked Tuerk to do—they discovered they were onto something big. It was 1989, the day before Thanksgiving, and Tuerk came running out of the darkroom where he’d been working. “That afternoon, it was clear to us he had done something that had lots of possibilities for the future in biotech, and we covered a whiteboard with every idea we had,” said Gold.

It was a watershed moment that would change the biotech industry significantly. “Craig and I shared the most wonderful moment possible for scientists: we imagined a future in which RNAs were ‘shapes, not tapes’ or ‘strings, not things’ and were useful in the same way that monoclonal antibodies are useful,” Gold wrote in a 2015 article in the Journal of Molecular Evolution.

In the process, the group isolated the first-known aptamers, a class of molecules with the unique binding ability—the keys—they were looking for. Then, they devised a system called SELEX (Systematic Evolution of Ligands by Exponential Enrichment), which could generate aptamers reliably and efficiently.

That discovery and development revolutionized biological research and medical diagnostics with wide-ranging applications from biomarker detection (indicating diseases like cancer and viral infections) to targeted therapies with fewer side effects.

From ��ý�Ļ��Ʒ to the world

The Path to Commercialization

When a university startup is created, it is the culmination of years of research and significant work by the founders to build a compelling company vision, strategy and business model. The team at Venture Partners is here to help with each step along the way, including:

intellectual property (IP) services,
entrepreneurial training through the I-Corps^TM Hub West,
a network of industry mentors,
funding through the Lab Venture Challenge,
the Ascent Deep Tech Accelerator,
fast and simple IP licensing through the Licensing with EASE^® program,
and many other resources.

Remarkable biotechnology breakthroughs don’t happen often, and even fewer enter the marketplace—and with such exceptional results. But Gold seems to have a knack for bringing them to light, combining decades of experience with a passion for inquiry. “You have to do the mundane work, but you also have to try to ask big questions, too,” he said, “Most people don't do that because they're afraid; our culture, in general, breeds a fear of failure.”

But to make the big discoveries, Gold said scientists have to take chances and cling to small victories in the process. “You should take some shots that are slightly ridiculous,” he said. “And enjoy all these little moments along the way where you learn something. The business of science for me is incredibly fun, and so that makes it easy to do for a long time.”

Since Gold and colleagues developed the SELEX platform, various academic and biopharma partners have also used it to develop new diagnostic tests, discover new drugs, accelerate their translation to clinical practice and reveal a deeper understanding of basic human biology and disease. In one such collaboration, Imperial College London is using a SomaLogic platform to analyze tens of thousands of biological samples as part of an investigation into how lifestyle, diet, genetic, metabolic and other factors affect the development of serious illnesses.

Soon after developing SELEX, Gold co-founded and served as co-director of research at Synergen, Inc., a biotechnology company later acquired by Amgen, Inc. and he founded NeXagen, Inc. (later called NeXstar Pharmaceuticals, Inc.), which merged with Gilead Sciences, Inc. in 1999. One major accomplishment of NeXstar centered on Macugen, a drug used to treat age-related macular degeneration and only the second-ever RNA aptamer to gain FDA approval.

Innovation that keeps on giving

Recognizing there was still work to be done in developing accessible diagnostics, Gold launched SomaLogic in 2000 where he served as CEO and chairman. He knew that focusing on proteomics—the field of measuring proteins—would be tough but, he wrote, “We also believed (and I continue to believe) that medical diagnostics was not as useful for patients and healthcare as it had to be, and that personalized medicine would depend on genomics and proteomics (and other ‘omics’ technologies).”

Based on the original SELEX technology developed at ��ý�Ļ��Ʒ, SomaLogic pioneered the development of proteomics diagnostics and experiments. That is, they set out to create arrays of aptamers (keys) to fit thousands of proteins (locks) simultaneously to make disease discovery as simple as possible. Their unique “SOMAmers” can distinguish between nearly identical proteins and their SomaScan Assay is the first and only platform enabling 11,000 protein measurements from a tiny fluid sample.

Spinning three companies out of a single innovation developed at ��ý�Ļ��Ʒ was an incredible feat, according to Bryn Rees, associate vice chancellor for research and innovation and managing director of Venture Partners at ��ý�Ļ��Ʒ. “Larry was a pioneer and did this at a time when universities really weren’t set up to support that,” said Rees. “It was transformative. None of the whole innovation ecosystem that we currently have would exist without Larry doing that. The whole thing is a major ��ý�Ļ��Ʒ success story.”

Venture Partners, the commercialization arm for ��ý�Ļ��Ʒ, now has myriad programs to help would-be entrepreneurs launch their innovations into the world. “Fast forward to today where it’s a wholesale culture change, and the university really understands how intertwined the mission of the university is, with folks like Larry being able to spin their work out and impact so many, in his case, patients and labs around the world,” said Rees.

In 2021, SomaLogic went public, and in January 2024, it merged with Standard BioTools Inc., which uses next-generation technologies to transform scientific discoveries into better patient outcomes.

The sky’s the limit when thinking about how the discoveries originally made at ��ý�Ļ��Ʒ will continue to be used to improve healthcare, Gold wrote. “…the future for applications of aptamers will be limited only by our imaginations…”

Founded by ��ý�Ļ��Ʒ Professor Larry Gold in 2000, SomaLogic revolutionized protein measurement by developing a faster, cost-effective process to monitor the vast number of proteins in the human body.

Off

Traditional

White

JILA-based innovation team Flari Tech wins ��ý�Ļ��Ʒ’s 2024 Lab Venture Challenge for breakthrough breath diagnostic technology targeting lung cancer

Daniel Corbin Leonard — Tue, 29 Oct 2024 18:32:13 +0000

JILA-based innovation team Flari Tech wins ��ý�Ļ��Ʒ’s 2024 Lab Venture Challenge for breakthrough breath diagnostic technology targeting lung cancer Daniel Corbin … Tue, 10/29/2024 - 12:32

JILA—Flari Tech Inc., a startup rooted in cutting-edge JILA research, has clinched one of the prestigious 2024 Lab Venture Challenge (LVC) grants from the University of Colorado Boulder, advancing its pioneering work to build a breathalyzer for diagnostics use targeting life-threatening diseases such as lung cancer.

Off

Traditional

White

$1.25M awarded to University of Colorado innovators to advance their discoveries

Daniel Corbin Leonard — Mon, 28 Oct 2024 21:10:46 +0000

$1.25M awarded to University of Colorado innovators to advance their discoveries Daniel Corbin … Mon, 10/28/2024 - 15:10

Daniel Leonard

Fourteen teams of University of Colorado faculty, researchers and graduate student innovators competed for a combined $1.25 million in startup funding grants in this year’s Lab Venture Challenge (LVC). Judges from ��ý�Ļ��Ʒ’s entrepreneurial network heard Shark-Tank-style pitches across two nights, one for innovations in biosciences and another for physical sciences and engineering.

Interested in the 2025 LVC?

LVC supports CU projects that address a commercial need, have a clear path to a compelling market and have strong scientific support.

Learn More

Through LVC, top innovators from ��ý�Ļ��Ʒ, Denver and Colorado Springs compete for grants of up to $125,000. LVC supports projects that address a commercial need, have a clear path to a compelling market and have strong scientific support. The LVC grants are funded by the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Program, as well as Venture Partners at ��ý�Ļ��Ʒ and the Chancellor’s Innovation Fund. Ten awards were granted this year for a total of $1,250,000.

This culminating event for these groundbreaking teams showcased the university’s initiative to support innovators from discovery to economic success. LVC is run by Venture Partners at ��ý�Ļ��Ʒ, the university’s commercialization arm and central resource for researchers who wish to translate their work into impactful business and social ventures. As part of the LVC program, all the competitors worked with Venture Partners to protect their innovations and practice their funding pitches for business audiences. LVC awardees will continue to work and collaborate with Venture Partners on their path to commercialization.

“At this early stage, funding is essential, but can be a challenge to obtain,“ said Joshua Bennett, director of LVC and senior licensing manager at Venture Partners. “All of these teams have promising innovations ready to launch new businesses. LVC is a unique opportunity for those innovators to receive that vital funding, and we’re proud to work with the State of Colorado to make it happen..”

To date, LVC has funded over 117 projects through 64 new deep-tech startup companies; collectively, these companies have raised over $349 million in follow-on financing.

Applications for the next LVC will open in July 2025.

This year’s LVC was additionally made possible by Berg Hill Greenleaf Ruscitti LLP, Wilson Sonsini, Cooley and Cozen O'Connor.

2024 Physical Sciences $125,000 Winners

Winners of the physical sciences competition from left to right: Gerry Conroy, Gregor P. Henze and Galen Williams of WHISPER Energy; Joshua Bennett, director of the Lab Venture Challenge (LVC); Roberta Leão of EcoValeric Innovations; Anthony Straub, Kian Lopez of OsmoPure Technologies; Gregory Whiting, Taylor Sharpe of Tierra Metrics; Thomas R. Schibli of Mode-Locked Laser Technology. Photo: Keanan Wilson.

EcoValeric Innovations

EcoValeric's invention is an electrochemical process that converts biomass-based levulinic acid into 4-hydroxyvaleric acid (HVA), a versatile intermediate for producing biodegradable plastics, biofuels and green solvents. This scalable, renewable process reduces reliance on fossil fuels while enhancing sustainability. ��ý�Ļ��Ʒ EcoValeric's website

Roberta Leão (��ý�Ļ��Ʒ Embark EIR): CEO, LVC Pitch Presenter
Adam Holewinski (��ý�Ļ��Ʒ Chemical and Biological Engineering): PI
Will Lucas: CTO

Mode-Locked Laser Technology

This groundbreaking mode-locked laser technology overcomes the limitations of existing systems and is suitable for harsh environments. These systems excel in applications that require the best phase noise performance in a small and efficient device. Applications include PNT and RF instrumentation.

Thomas R. Schibli (��ý�Ļ��Ʒ Physics): PI, LVC Pitch Presenter
Chris Singer (Alum: ��ý�Ļ��Ʒ Business): Business Development
Christopher B. Oei: Product Design, Advanced Manufacturing

OsmoPure Technologies

OsmoPure is introducing a membrane for ultrapure water production tailored to the stringent demands of electronics, aerospace and green hydrogen sectors. The technology uses distillation driven by pressure, rather than heat, to produce high-purity product water with ten times higher energy efficiency. ��ý�Ļ��Ʒ the OsmoPure website

Kian Lopez (PhD student, ��ý�Ļ��Ʒ Chemical and Biological Engineering): CEO, LVC Pitch Presenter
Anthony Straub (��ý�Ļ��Ʒ Civil, Environmental, and Architectural Engineering): Principal Investigator (PI)
Nadia Jorgenson (PhD candidate, ��ý�Ļ��Ʒ Civil, Environmental, and Architectural Engineering): Director of R&D

WHISPER Energy

WHISPER Energy is a wireless, battery-free sensor platform for smart buildings. It uses machine learning to cut energy consumption by 30%+, providing real-time data to optimize energy use and reduce emissions. Developed with a $2 million ARPA-E grant, it advances zero emissions economically and efficiently. ��ý�Ļ��Ʒ the WHISPER website

Galen Williams (��ý�Ļ��Ʒ 2023 Embark EIR): Co-Founder and CEO
Gregor P. Henze (��ý�Ļ��Ʒ Civil, Environmental and Architectural Engineering, RASEI): PI and Co-Founder
Gerry Conroy: Technical Lead and Advisor

Tierra Metrics

Tierra Metrics' novel high-spatial density sensor innovation will enable real-time characterization of the soil nitrogen cycle which will help growers, land managers and others to improve efficiency and profitability, as well as improve soil health and mitigate greenhouse gas emissions. ��ý�Ļ��Ʒ the Tierra Metrics website

Gregory Whiting (��ý�Ļ��Ʒ Paul M. Rady Mechanical Engineering): PI, LVC Pitch Presenter
Taylor Sharpe (��ý�Ļ��Ʒ Paul M. Rady Mechanical Engineering) Chief Engineer
Whendee Silver: Co-Founder
Ana Claudia Arias: Co-Founder

2024 Biosciences $125,000 Winners

Winners of the biosciences competition from left to right: Emmalee Biesiada of Sterio3; Eva Yao of Flari Tech; Tanya Warnecke of Codebreaker; Jesse M. Sheppard of IntraLumenus; Makenna Morck, Alec Santiago, Michael Stowell of Kitsune Bio. Photo: Keanan Wilson.

Codebreaker

Codebreaker is building a platform for generating variant genomes at scale in an AI framework that drives variant genome design and machine learning to generate significance maps broadly across human disease and drug response.

Ryan Layer (BioFrontiers Institute: PI, LVC Pitch Presenter
Ryan T. GIll: CEO
Tanya Warnecke: CTO
Jordan Abbott: KOL-Collaborator

Flari Tech

Flari Tech is building a laser-based breathalyzer to detect lung cancer noninvasively and rapidly with high sensitivity. Powered by CU's Nobel Prize-winning optical frequency comb, it would empower healthcare providers, patients and researchers in lung cancer prevention, treatment and monitoring. Read more about Flari

Eva Yao (��ý�Ļ��Ʒ 2023 Embark EIR): CEO, LVC Pitch Presenter
Jun Ye (��ý�Ļ��Ʒ Physics, JILA): PI
Qizhong Liang (PhD candidate, ��ý�Ļ��Ʒ Physics, JILA): Technical Lead
Apoorva Bisht (PhD student, ��ý�Ļ��Ʒ Physics, JILA): Research Assistant

Kitsune Bio

Kitsune Bio enhances the structural adaptability of cyclic peptides, improving their ability to bind, inhibit and access challenging intracellular targets. This unique platform unlocks new opportunities for treating complex diseases and improving patient outcomes.

Makenna Morck (��ý�Ļ��Ʒ Embark EIR): CEO, LVC Pitch Presenter
Alec Santiago (��ý�Ļ��Ʒ Embark EIR): COO, LVC Pitch Presenter
Michael Stowell (��ý�Ļ��Ʒ Molecular, Cellular & Developmental Biology): PI

IntraLumenus

Let’s never cut open a patient again. IntraLumenus is a treaded robotic capsule endoscope that travels through the colon under its own power, provides localization and mapping, and dual channel tool access, enabling colorectal procedures to be performed intraluminally, or from within the colon.

Jesse M. Sheppard (��ý�Ļ��Ʒ Embark EIR): CEO, LVC Pitch Presenter
Mark Rentschler (��ý�Ļ��Ʒ Paul M. Rady Mechanical Engineering): PI

SteriO3

Peroxide Enhanced Germicidal Irradiation (PEGI) provides rapid, low-resource sterilization of microbial contaminants. With adaptable configuration capabilities, PEGI will be engineered into compact, portable units for low-temperature sterilization of surgical equipment, including 3D-printed implants. ��ý�Ļ��Ʒ the SteriO3 website

Emmalee Biesiada (��ý�Ļ��Ʒ Civil, Environmental and Architectural Engineering): Principal Investigator (PI), LVC Pitch Presenter
Steve Hughes: CEO
Mark Hernandez (��ý�Ļ��Ʒ Civil, Environmental and Architectural Engineering): Chief Scientific and Project Advisor

Vesicle Therapeutics

The Vesicle team is developing a proprietary STAT3 isoform-selective antisense oligonucleotide (ASO) using novel thiomorpholino chemistry (TMO) for the treatment of head and neck cancer is the sixth most common cancer type, with a low survival rate due to poor responsiveness to treatments.

Xuedong Liu (��ý�Ļ��Ʒ Biochemistry): PI, LVC Pitch Presenter
Donna Peak: CEO
Curtis Woodard: COO
Gan Zhang: CTO
Marvin H. Caruthers (��ý�Ļ��Ʒ Biochemistry): Collaborator

Fourteen teams of University of Colorado faculty, researchers and graduate student innovators competed for a combined $1.25 million in startup funding grants in this year’s Lab Venture Challenge (LVC).

Off

Traditional

White

New device could deliver bedside blood test results in an hour

Daniel Corbin Leonard — Wed, 16 Oct 2024 22:09:24 +0000

New device could deliver bedside blood test results in an hour Daniel Corbin … Wed, 10/16/2024 - 16:09

��ý�Ļ��Ʒ Today—Go to the doctor to provide a blood sample and you’re typically faced with a needle and syringe and hours or even days of waiting to get results back from a lab. ��ý�Ļ��Ʒ researchers hope to change that with a new handheld, sound-based diagnostic system able to deliver precise results in an hour with a mere finger prick of blood.

Off

Traditional

White

New handheld device promises rapid blood diagnostics

Daniel Corbin Leonard — Wed, 16 Oct 2024 17:48:28 +0000

New handheld device promises rapid blood diagnostics Daniel Corbin … Wed, 10/16/2024 - 11:48

News-Medical—Patients who go to the doctor to provide a blood sample are typically faced with a needle and syringe and hours or days of waiting to get results back from a lab. ��ý�Ļ��Ʒ researchers hope to change that with a new handheld, sound-based diagnostic system to deliver precise results in an hour with a mere finger prick of blood.

Off

Traditional

White

��ý�Ļ��Ʒ research funding more than doubled in the last decade

Daniel Corbin Leonard — Mon, 14 Oct 2024 17:57:44 +0000

��ý�Ļ��Ʒ research funding more than doubled in the last decade Daniel Corbin … Mon, 10/14/2024 - 11:57

Daily Camera—Research funding at the University of Colorado Boulder has more than doubled in the last decade, increasing by about $391 million. There were 35 ��ý�Ļ��Ʒ-affiliated startup companies this last fiscal year compared to 10 the year before.

Off

Traditional

White

��ý�Ļ��Ʒ spinoff Inscripta launches the world's first benchtop platform for digital genome engineering

Anonymous — Thu, 10 Oct 2019 15:55:32 +0000

��ý�Ļ��Ʒ spinoff Inscripta launches the world's first benchtop platform for digital genome engineering Anonymous (not verified) Thu, 10/10/2019 - 09:55

The Onyx™ platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow.

Off

Traditional

White

Biosciences

SomaLogic, spun out of the Gold Lab at ����������ý�Ļ���Ʒ, revolutionized protein discovery methods to provide insights into disease discovery and treatment

Imagining a bold future

From ����������ý�Ļ���Ʒ to the world

Innovation that keeps on giving

Off

JILA-based innovation team Flari Tech wins ����������ý�Ļ���Ʒ’s 2024 Lab Venture Challenge for breakthrough breath diagnostic technology targeting lung cancer

Off

$1.25M awarded to University of Colorado innovators to advance their discoveries

2024 Physical Sciences $125,000 Winners

EcoValeric Innovations

Mode-Locked Laser Technology

OsmoPure Technologies

WHISPER Energy

Tierra Metrics

2024 Biosciences $125,000 Winners

Codebreaker

Flari Tech

Kitsune Bio

IntraLumenus

SteriO3

Vesicle Therapeutics

Off

New device could deliver bedside blood test results in an hour

Off

New handheld device promises rapid blood diagnostics

Off

����������ý�Ļ���Ʒ research funding more than doubled in the last decade

Off

����������ý�Ļ���Ʒ spinoff Inscripta launches the world's first benchtop platform for digital genome engineering

Off

SomaLogic, spun out of the Gold Lab at ��ý�Ļ��Ʒ, revolutionized protein discovery methods to provide insights into disease discovery and treatment

From ��ý�Ļ��Ʒ to the world

JILA-based innovation team Flari Tech wins ��ý�Ļ��Ʒ’s 2024 Lab Venture Challenge for breakthrough breath diagnostic technology targeting lung cancer

��ý�Ļ��Ʒ research funding more than doubled in the last decade

��ý�Ļ��Ʒ spinoff Inscripta launches the world's first benchtop platform for digital genome engineering